Aligos Therapeutics’ Post

The Art of the Strategic Pivot: Lessons from Pfizer's Metsera Acquisition Pfizer's announcement of its $7.3 billion deal to acquire Metsera offers a powerful lesson in corporate strategy. After facing setbacks with its own internal obesity drug development, Pfizer has demonstrated the wisdom of a strategic pivot. Instead of doubling down on a struggling internal program, they have made a decisive move to acquire a promising external pipeline. This isn't just about buying a company; it's about buying a future. The obesity drug market is projected to be worth $100 billion by the 2030s, and Pfizer's acquisition of Metsera positions them as a serious contender in this lucrative space. For business leaders, the key takeaway is this: while internal innovation is vital, the ability to recognize when to shift gears and embrace external opportunities is a hallmark of true leadership. It requires humility to acknowledge setbacks and the courage to make bold, strategic acquisitions that can reshape a company's future. In a rapidly evolving market, agility and foresight are the ultimate competitive advantages. #BusinessStrategy #Leadership #MergersAndAcquisitions #Pharmaceuticals #Innovation

Reflecting on my journey, I've learned that empowering your team through connection and collaboration truly transforms how we navigate challenges. In the pharmaceutical and life sciences industries, leaders face complex compliance hurdles every day. The key takeaway? Foster a culture where curiosity thrives and open communication flows. How has connection impacted your leadership experience? Share your thoughts or tips in the comments! #LifeSciences #Community #Pharmaceutical #Collaboration #Empowerment #Leadership #Consulting

“You have to start your day thinking about doing great work with good people and not let obstacles get in your way. The possibilities are endless.” McKinsey Senior Partner Jan Ascher recently sat down with Elcin Barker Ergun, CEO of Menarini Group, to discuss her approach to innovation and leadership at the pharmaceutical company. She shares how she has spearheaded change while building a global innovative oncology business, what she thinks it will take to unlock more innovation productivity in the industry, and her advice for young leaders looking to make an impact here: https://lnkd.in/ec2GaePh #pharma #biopharma #leadership

💡 “A high-functioning Board is one that enhances the leadership team rather than merely overseeing it.” - Dr. Juho Jalkanen MD, PhD, CEO and Founder of Faron Pharmaceuticals   In our latest Board Practice Newsletter published by Tanya Gass, Life Sciences Partner Luke Horrigan speaks with Dr. Juho about how strong Board dynamics, strategic focus, and investor engagement have helped Faron stand out in a tough biotech market. Key to their progress has been:   - A laser focus on delivering value-driving clinical and regulatory milestones - A Board that provides unvarnished guidance, bold decision-making, and active investor engagement - A culture of collaboration and trust between Board and management, even through tough decisions Read the full conversation here: https://lnkd.in/etCeYt7k

In this quarter's board practice newsletter, there are some interesting insights about a rapidly evolving sector from Luke Horrigan's conversation with Juho Jalkanen MD, PhD, Founder and CEO of Faron, one of the businesses we've been supporting over the last 12 months

I really enjoyed the final episode from Sophie Bradley's Next Generation Pharma Growth series. It's a great breakdown of the considerations we need to take to stay ahead, including looking at who companies are competing with, how to create value and what it means to lead in the next generation of pharma growth. Have a watch below!

In today's episode of #StraightTalkingSustainability, Emma Burlow talks to Silja Chouquet, a former pharmaceutical executive turned social entrepreneur. Silja's journey from pharmaceutical strategy consulting to creating her own social enterprise (Marikoi, which brought patient experts into pharma boardrooms) gives her unique insight into both worlds. Tune in to the episode for more of her insights. #sustainabilitypodcast

Throwback to a 2008 pharmaceutical conference when Denise Morris was mistaken for being in marketing or sales just because of how she looked. It was one of those moments that revealed how deeply stereotypes still run in the scientific community. “They Said What?”, the first podcast from Denise Morris at Emerald City Pharma Consulting, examines these perceptions and reminds us why amplifying diverse voices in biopharma matters. As we continue that mission, our new series, “Unsung Heroes in Pharma”, will shine a light on the overlooked innovators, change-makers, and boundary-breakers shaping the future of our industry. Haven’t listened yet (or want to revisit your favorites)? Now’s the perfect time to catch up on past episodes of “They Said What?” at www.emeraldcitypharma.com ahead of the launch of “Unsung Heroes in Pharma”! #EmeraldCityPharma #YourCROGuide

What is happening in the CDMO space? Symeres names GABRIELLA GENTILE COO to strengthen their operations FairJourney Biologics names Werner Lanthaler as CEO whilst the Founder António Parada moves to the Supervisory Board to drive innovation. Wheeler Bio, Inc. names Jay Benson as COO to help scale US manufacturing Lonza - Maria Soler moves from Head of Group Operations to Chief Quality Officer Mabion S.A. appoints Gregor Kawaletz as CEO, strengthening their leadership team a

In the final episode of the Next Generation Pharma Growth series, my colleague Sophie Bradley considers that to stay ahead, we need to look at: 🌟Who companies are competing with 📈How to create value 🚀What it means to lead in the next generation of pharma growth. Watch now to find out more.